BTC $79,769.74 -0.76%
ETH $2,301.85 -1.75%
BNB $740.00 +0.05%
XRP $1.29 -0.78%
SOL $100.17 -1.34%
TRX $0.3297 -0.16%
DOGE $0.0770 -0.07%
ADA $0.2042 -0.37%
BCH $277.58 -0.70%
LINK $11.32 -1.23%
HYPE $77.54 +0.69%
AAVE $134.40 -1.78%
SUI $0.9055 -2.02%
XLM $0.1676 -0.44%
ZEC $1,219.21 +0.56%
AAPL $344.40 -0.78%
AMZN $249.32 +0.05%
GOOGL $317.98 -1.06%
MSFT $533.45 +1.85%
META $634.28 -1.37%
NVDA $216.40 +1.66%
TSLA $392.19 +5.01%
SNDK $1,260.52 -0.05%
INTC $91.13 +4.35%
SPCX $147.50 -0.85%
MU $905.96 +1.45%
AMD $532.59 +1.89%
BTC $79,769.74 -0.76%
ETH $2,301.85 -1.75%
BNB $740.00 +0.05%
XRP $1.29 -0.78%
SOL $100.17 -1.34%
TRX $0.3297 -0.16%
DOGE $0.0770 -0.07%
ADA $0.2042 -0.37%
BCH $277.58 -0.70%
LINK $11.32 -1.23%
HYPE $77.54 +0.69%
AAVE $134.40 -1.78%
SUI $0.9055 -2.02%
XLM $0.1676 -0.44%
ZEC $1,219.21 +0.56%
AAPL $344.40 -0.78%
AMZN $249.32 +0.05%
GOOGL $317.98 -1.06%
MSFT $533.45 +1.85%
META $634.28 -1.37%
NVDA $216.40 +1.66%
TSLA $392.19 +5.01%
SNDK $1,260.52 -0.05%
INTC $91.13 +4.35%
SPCX $147.50 -0.85%
MU $905.96 +1.45%
AMD $532.59 +1.89%

hest

All
Article
Flash

first_img OpenAI acquires Orchestra Bio, AI entities take over drug development

OpenAI announced the acquisition of San Francisco startup Orchestra Bio, which has developed AI agents to help pharmaceutical companies track the progress of drug development projects. Orchestra's team and platform will be integrated into OpenAI's life sciences product line Rosalind, aimed at biologists and chemists, with the transaction amount undisclosed. Orchestra was founded in the fall of 2022, with seed funding from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, raising a total of approximately $20 million.According to OpenAI, a new drug can take up to 15 years from initial conception to approval in the United States, and the cost of bringing a single approved drug to market can exceed $2.6 billion, with less than 10% of candidate drugs entering human trials ultimately reaching the market. Orchestra's AI agents can automatically monitor tasks and flag issues, analyze how setbacks like production batch failures affect the overall development project, compile relevant information, and compare response strategies, ultimately allowing scientists and project leaders to make decisions.This acquisition follows competitor Anthropic's acquisition of Coefficient Bio for approximately $400 million in April, reflecting the competition among AI labs for new drug development workflows. In April, OpenAI launched the model GPT-Rosalind specifically designed for biology and drug discovery, available only to vetted U.S. corporate clients such as Amgen and Moderna, with the accompanying product Rosalind Workbench connecting the model to research tools and data.

CryptoQuant: Short-term on-chain profit margins hit the highest since December 2024, Bitcoin may face a correction

According to a report by The Block, CryptoQuant's research director Julio Moreno pointed out that Bitcoin's closing price last week was above the 365-day moving average, confirming the start of a new bull market. However, Moreno stated that after Bitcoin reached an eight-month high of $87,400, several indicators show that upward momentum is weakening, and a market correction may follow.The report noted that the on-chain unrealized profit margin for short-term traders has risen to 33%, the highest level since December 2024. Historically, when profit margins are at similar levels, it often prompts traders to take profits. Data shows that on September 22, Bitcoin holders realized profits of 25,700 BTC in a single day, setting a record for the highest daily profit since 2026; the altcoin market also showed signs of selling pressure. The seven-day cumulative number of altcoin transactions rose to 76,000, the highest level since October 17, 2025. Meanwhile, spot demand continues to shrink, and the growth of futures demand has significantly slowed.After Bitcoin previously reached an eight-month high of around $87,400, the upward momentum has shown signs of fatigue. Julio Moreno indicated that if a correction occurs, the 365-day moving average (around $80,000) will serve as the primary support, followed by the 200-day moving average (around $71,000) and the on-chain realized price for traders (around $67,000). Provided that the support levels hold, this correction is more likely to be a healthy consolidation in a young bull market rather than a trend reversal.
app_icon
ChainCatcher Building the Web3 world with innovations.